Key result
Cross-tapering zuclopenthixol depot to oral clozapine linked to neuroleptic malignant syndrome.
Cross-tapering from a typical depot medication to an oral atypical antipsychotic carries a risk of neuroleptic malignant syndrome.
Raises caution for NMS during antipsychotic cross-tapering; case report leaves open generalizability and need for prospective confirmation.
A 32-year-old male patient with a history of treatment resistant paranoid schizophrenia developed neuroleptic malignant syndrome (NMS) during changeover of his antipsychotic medication from zuclopenthixol depot to clozapine. This case highlights the difficulties of cross-tapering two antipsychotics-that is, converting from a typical depot medication to an oral atypical antipsychotic.
No takes yet. Share an insight, caveat, or question.
Kuchibatla et al. (2009) studied this question. Cross-tapering antipsychotic medication from zuclopenthixol depot to oral clozapine precipitated neuroleptic malignant syndrome in a patient with treatment-resistant schizophrenia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: